Trending Now: (CMMB) Lights Up Multiple Bullish Signals—Surpassing Several Key Technical Levels

*Sponsored All Eyes on Chemomab Therapeutics (Nasdaq: CMMB) This Morning—Here’s Why It’s Topping Our Thursday Watchlist… For Starters: Chemomab Therapeutics (Nasdaq: CMMB) Has A Low Float Under 17M Shares—This Could Amplify Potential Moves If Demand Begins To Shift. Maxim Group’s $7.00 Target On Chemomab Therapeutics (Nasdaq: CMMB) Suggests Over 530% Upside Potential. RSI Below 30 Places Chemomab Therapeutics (Nasdaq: CMMB) In Classic “Oversold” Territory—Potentially Paving The Way For A Quick Trend Reversal.  FDA Alignment On A Streamlined Late-Stage Trial Could Accelerate Chemomab Therapeutics (Nasdaq: CMMB)’s Next Milestone… And With A Market Cap Below $21M Chemomab Therapeutics (Nasdaq: CMMB) Appears To Be Flying Well Below Most Radar Screens—Until Now.  Take A Look At Chemomab Therapeutics (Nasdaq: CMMB) While It's Still Early… March 27, 2025 Dear Reader, Have You Pulled Up (CMMB) Yet? It’s still flying well under the radar—with fewer than 17M shares in its float. And yet, it just dropped fresh data that supports long-term activity, clinical impact, and a streamlined Phase 3 pathway in one of the most challenging rare liver conditions out there. Despite the early move this morning, (CMMB) is still hovering in a range where just a spark of new attention could set things off. Chemomab Therapeutics (Nasdaq: CMMB) reached $1.38 in the early session, marking an approximate 18% move from yesterday’s $1.16 close—surpassing several key moving averages and triggering multiple bullish signals on TradingView’s dashboard.  If (CMMB) isn’t already on your screen—now might be the time to change that. Biotech and pharma are some of the most exciting industries, where a single breakthrough can turn an under-the-radar company into a major market player overnight. This one has a float of less than 17M shares, which could set the stage for significant swings if attention starts to shift. Its market cap sits under $21M—a range where little-known companies have historically made their biggest moves when the right catalyst hits. And that catalyst may have just arrived: regulatory alignment that places it on track for a pivotal late-stage study targeting a serious condition with no approved therapies. We’re talking about Chemomab Therapeutics (Nasdaq: CMMB)—and the situation here is hard to ignore. With early-stage results already showing encouraging signals—and the FDA aligned on an efficient Phase 3 design—this clinical-stage company could be entering a critical stretch that few have spotted. Michael Okunewitch, a Senior Research Analyst at Maxim Group, recently set a $7.00 target on Chemomab Therapeutics (Nasdaq: CMMB)—which suggests over 530% upside potential from Wednesday’s $1.11 open. That’s not just a projection—it’s a clear signal that something may be taking shape beneath the surface. With a float under 17M shares and a market cap below $21M, this is still very much under the radar—exactly where some of the biggest moves tend to begin. And with its RSI levels dipping below 30, Chemomab Therapeutics (Nasdaq: CMMB) appears to be heading towards “oversold territory” and potentially paving the way for a quick trend reversal.  Keep reading to see why Chemomab Therapeutics (Nasdaq: CMMB) is topping our watchlist this morning. The company’s lead program is targeting a rare and devastating liver condition where no approved therapies exist—one with significant unmet need and growing urgency. The Focus: Primary Sclerosing Cholangitis (PSC) – A Rare Disease With High Unmet Need PSC is a serious, progressive liver disease that affects approximately 80,000 people across the U.S., Europe, and Japan.  Characterized by inflammation and fibrosis of the bile ducts, it leads to liver failure, cancer, and often requires a transplant.  Yet to this day—there are no approved therapies. That’s where Nebokitug comes in. Unlike other candidates in development, Nebokitug targets CCL24, a molecule believed to play a central role in both the inflammatory and fibrotic pathways driving PSC.  Blocking CCL24 has been shown to: Reduce immune cell recruitment Suppress fibroblast activation Break the self-reinforcing cycle of disease progression And Chemomab Therapeutics (Nasdaq: CMMB) isn’t just speculating.  They’ve demonstrated safety and mechanism-based activity in five clinical trials, spanning multiple inflammatory and fibrotic conditions. Nebokitug: A Novel Mechanism with Broad Validation Multiple Phase 2 outcomes met: Improved biomarkers for inflammation, fibrosis, and cholestasis Dose-dependent pharmacokinetics and engagement confirm target impact Patients with more advanced PSC saw the most benefit—a key detail for designing later-stage trials Favorable tolerability profile with no dr-ug-related serious adverse events reported Statistically significant improvements in liver stiffness, pruritus, and ELF scores—all important indicators of PSC severity Nebokitug may also be the only late-stage candidate to demonstrate consistent improvements across all three core aspects of PSC—fibrosis, inflammation, and bile duct function. FDA Engagement Sets Stage for Chemomab Therapeutics (Nasdaq: CMMB) Phase 3 Rollout… After its End-of-Phase 2 meeting with the FDA, Chemomab Therapeutics (Nasdaq: CMMB) received alignment on a clear and efficient pivotal trial design.  The planned Phase 3 study will use clinically meaningful event-based endpoints—measuring things like the need for transplant, hospitalization for liver complications, and disease progression markers. This design avoids the need for liver biopsies or complex long-term confirmatory studies, which could help streamline execution and reduce overall trial complexity compared to many rare disease studies. The company is preparing to initiate this study, with the final protocol expected to be locked in soon.  An Open Label Extension study is also set to deliver new data that could further strengthen the case for Nebokitug’s potential role in this space. Not Just PSC: A Pipeline That Could Expand… While PSC is the lead indication, Chemomab Therapeutics (Nasdaq: CMMB) is also exploring Nebokitug for Systemic Sclerosis (SSc)—another rare fibro-inflammatory disease.  This program is already Phase 2-ready, with an open U.S. IND, Orphan Designation, and robust preclinical evidence supporting its mechanism. Research has shown elevated CCL24 levels in SSc patients and strong associations between those levels and clinical severity.  Animal models and human samples alike suggest CCL24 blockade could reduce skin and lung fibrosis—key symptoms of this challenging condition. If PSC paves the way, SSc could open a second major path forward. Recent Developments New Data on Nebokitug Revealed at CORA 2025… Fresh findings presented at the CORA 2025 Conference have spotlighted Nebokitug's potential impact in systemic sclerosis—an aggressive autoimmune condition with limited options. Researchers shared updated preclinical data confirming that elevated CCL24 levels, Nebokitug’s target, are highly correlated with disease progression and organ damage.  The company also highlighted that blocking CCL24 led to reduced fibrosis markers and inflammation in lung and skin tissue models—two areas central to systemic sclerosis.  This adds to the scientific validation supporting future clinical development of Nebokitug in this indication. Chemomab Shares 2024 Highlights and Lays Out Strategic Priorities… Chemomab’s end-of-year corporate update offers a clear picture of momentum and focus heading into 2025. In this comprehensive summary, the company reiterated its progress advancing Nebokitug in primary sclerosing cholangitis (PSC), including strong safety signals and promising biomarker improvements from the Phase 2 SPRING trial.  They also pointed to preparations underway for the Phase 3 study, anticipated key milestones in systemic sclerosis, and an early 2026 cash runway. The update reinforces a disciplined approach to development while emphasizing continued scientific and operational execution. FDA Feedback Clears the Way for Next-Stage Nebokitug Trial… Chemomab successfully completed its End-of-Phase 2 meeting with the FDA, resulting in alignment on a clear, event-based design for the Phase 3 trial in PSC. The meeting confirmed that clinical events such as disease-related hospitalizations, liver function decline, or transplant need will be used as endpoints—potentially removing the need for invasive procedures like liver biopsies.  The design aims to track real-world impact while enabling broader patient inclusion. This milestone significantly streamlines the company’s path forward and positions Nebokitug as a potential leader in a space with no approved therapies to date. Bottom Line… Chemomab Therapeutics (Nasdaq: CMMB) is navigating forward with: A Phase 3-ready program targeting a serious rare disease with no approved options A differentiated mechanism of action backed by clinical and preclinical data A low-float structure that could amplify attention as momentum builds A high target from a respected analyst, bringing this name into focus With multiple near-term catalysts, a streamlined regulatory path, and a candidate demonstrating effects across critical biomarkers—Chemomab Therapeutics (Nasdaq: CMMB) could soon move out from under-the-radar. This is one little-known company to keep an eye on. 7 Reasons Why Chemomab Therapeutics (Nasdaq: CMMB) is Topping Our Watchlist This Morning…  1. Low Float: With fewer than 17M shares listed, Chemomab Therapeutics (Nasdaq: CMMB)’s tightly held structure could set the stage for significant swing potential—especially if demand starts to shift. 2. Analyst Target: Michael Okunewitch of Maxim Group recently issued a $7.00 target for Chemomab Therapeutics (Nasdaq: CMMB)—which suggests over 530% upside potential from yesterday’s open. 3. Under The Radar: Still flying under most radars, Chemomab Therapeutics (Nasdaq: CMMB)’s market cap is currently below $21M, well below typical biotech peers—yet its pipeline progress and regulatory positioning suggest it may be one company to keep an eye on. 4. Oversold Territory: With RSI dipping below 30, Chemomab Therapeutics (Nasdaq: CMMB) has entered technical “oversold” territory—an area that, historically, has often preceded short-term trend reversals in similar setups. 5. FDA Alignment: Following its End-of-Phase 2 meeting, Chemomab Therapeutics (Nasdaq: CMMB) received alignment from the FDA on a late-stage trial design using real-world clinical endpoints—no biopsies, no long confirmatory delays. 6. Phase 2 Data: The company’s lead candidate, Nebokitug, demonstrated safety and activity across key disease markers in PSC, including inflammation, fibrosis, and bile duct function—all with statistically significant results in target subgroups. 7. Pipeline Expansion: In addition to PSC, Chemomab Therapeutics (Nasdaq: CMMB) is preparing to advance its program into systemic sclerosis—another serious, underserved condition. With Orphan Designation and preclinical validation already in place, a second path forward may soon take shape. Consider Adding Chemomab Therapeutics (Nasdaq: CMMB) To Your Radar While It's Still Early… When you combine a low float with a low market cap, strong Phase 2 data, and a greenlight from the FDA to skip the usual roadblocks—you’re not looking at just another quiet biotech.  You're looking at a setup that’s been largely ignored… but might not stay that way for long. Chemomab Therapeutics (Nasdaq: CMMB) has all the characteristics of a sleeper setup—until something wakes it up.  With systemic sclerosis also in the pipeline and technicals pointing to oversold levels, this could be one of those names that goes from silence to spotlight faster than most are prepared for. Adding to the case, Michael Okunewitch of Maxim Group recently issued a $7.00 target on Chemomab Therapeutics (Nasdaq: CMMB) —a level that suggests over 530% upside potential from yesterday’s $1.11 range. We have all eyes on (CMMB) this morning. Chemomab Therapeutics (Nasdaq: CMMB) reached $1.38 in the early session, marking an approximate 18% move from yesterday’s $1.16 close—surpassing several key moving averages and triggering multiple bullish signals. If (CMMB) isn’t already on your screen—now might be the time to change that.  And please be on the look out for my next update—could be out at any time. Sincerely, Jeff Ackerman Managing Editor Stock News Trends StockNewsTrends.com (“StockNewsTrends” or “SNT” ) is owned by TD Media LLC, a single member limited liability company. Data is provided from third-party sources and StockNewsTrends is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SNT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owner of TD Media LLC owns and operates stocknewstrends . com (“SNT”). From time to time, SNT will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: stocknewstrends.com/disclosure/  *Pursuant to an agreement between TD Media LLC and JRZ Capital LLC, TD Media LLC has been hired for a period beginning on 03/26/2025 and ending on 03/27/2025 to publicly disseminate information about (CMMB:US) via digital communications. Under this agreement, TD Media LLC has been paid forty thousand USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither TD Media LLC and their member own shares of (CMMB:US). Please see important disclosure information here: https://lifewatermedia.com/disclosure/cmmb/#details

TD Media LLC | 5826 New Territory Blvd. Unit #2144 | Sugar Land, TX 77479 US Unsubscribe | Update Profile | Constant Contact Data Notice